| Autor: |
Bumes E; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, 93055 Regensburg, Germany., Fellner C; Department of Radiology and Division of Neuroradiology, Regensburg University Hospital, 93055 Regensburg, Germany., Fellner FA; Central Institute of Radiology, Kepler University Hospital, 4021 Linz, Austria., Fleischanderl K; Division of Molecular Pathology, Neuromed Campus, Kepler University Hospital, 4020 Linz, Austria., Häckl M; Institute of Functional Genomics, University of Regensburg, 93053 Regensburg, Germany., Lenz S; Division of Molecular Pathology, Neuromed Campus, Kepler University Hospital, 4020 Linz, Austria., Linker R; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, 93055 Regensburg, Germany., Mirus T; Institute of Functional Genomics, University of Regensburg, 93053 Regensburg, Germany., Oefner PJ; Institute of Functional Genomics, University of Regensburg, 93053 Regensburg, Germany., Paar C; Institute of Laboratory Medicine, Kepler University Hospital, 4021 Linz, Austria., Proescholdt MA; Department of Neurosurgery, Regensburg University Hospital, 93053 Regensburg, Germany., Riemenschneider MJ; Department of Neuropathology, Regensburg University Hospital, 93053 Regensburg, Germany., Rosengarth K; Department of Neurosurgery, Regensburg University Hospital, 93053 Regensburg, Germany., Weis S; Division of Neuropathology, Neuromed Campus, Kepler University Hospital, 4020 Linz, Austria., Wendl C; Department of Radiology and Division of Neuroradiology, Regensburg University Hospital, 93055 Regensburg, Germany., Wimmer S; Institute of Neuroradiology, Neuromed Campus, Kepler University Hospital, 4020 Linz, Austria., Hau P; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, 93055 Regensburg, Germany., Gronwald W; Institute of Functional Genomics, University of Regensburg, 93053 Regensburg, Germany., Hutterer M; Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, 93055 Regensburg, Germany.; Department of Neurology with Acute Geriatrics, Saint John of God Hospital Linz, 4021 Linz, Austria. |
| Abstrakt: |
The isocitrate dehydrogenase ( IDH ) mutation status is an indispensable prerequisite for diagnosis of glioma (astrocytoma and oligodendroglioma) according to the WHO classification of brain tumors 2021 and is a potential therapeutic target. Usually, immunohistochemistry followed by sequencing of tumor tissue is performed for this purpose. In clinical routine, however, non-invasive determination of IDH mutation status is desirable in cases where tumor biopsy is not possible and for monitoring neuro-oncological therapies. In a previous publication, we presented reliable prediction of IDH mutation status employing proton magnetic resonance spectroscopy ( 1 H-MRS) on a 3.0 Tesla (T) scanner and machine learning in a prospective cohort of 34 glioma patients. Here, we validated this approach in an independent cohort of 67 patients, for which 1 H-MR spectra were acquired at 1.5 T between 2002 and 2007, using the same data analysis approach. Despite different technical conditions, a sensitivity of 82.6% (95% CI, 61.2-95.1%) and a specificity of 72.7% (95% CI, 57.2-85.0%) could be achieved. We concluded that our 1 H-MRS based approach can be established in a routine clinical setting with affordable effort and time, independent of technical conditions employed. Therefore, the method provides a non-invasive tool for determining IDH status that is well-applicable in an everyday clinical setting. |
